Eli Lilly delivered strong second-quarter results that surpassed Wall Street expectations, driven by robust sales of its weight loss and diabetes medications. The company reported earnings per share of $8.38 against analyst estimates of $6.01, while revenue reached $22.97 billion compared to the anticipated $20.73 billion. The pharmaceutical firm raised its full-year revenue guidance to between $85 billion and $87 billion, an increase from the previous $82 billion to $85 billion range.
The company’s flagship treatments continued to perform exceptionally well. Mounjaro, its diabetes drug, generated $9.94 billion in worldwide revenue for the quarter, significantly outpacing analyst expectations of $8.99 billion. Zepbound, the weight loss medication, contributed $4.93 billion in U.S. sales, exceeding the projected $4.69 billion. Notably, international markets demonstrated particular strength, with non-U.S. revenue jumping 80 percent overall, reflecting expanded global demand for these treatments.
Eli Lilly also introduced its newly approved obesity pill, Foundayo, which generated $98 million in sales during the quarter. The pharmaceutical giant saw prescription volumes increase 37 percent domestically, primarily attributed to its blockbuster medications, though this growth was partially offset by lower realized prices. Stock market investors responded positively to the earnings announcement, with shares rising more than 5 percent in premarket trading.
About the Author
